His figures sound real. I expect the initial negative impact on Copaxon's sales from Tecfidera's extra-forte strong launch to slow (my guess is that NRx is already up a bit from 25%). To what degree depends on how well patients will do on Tecfidera in the long run.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.